Skip to main content
Clinical Trials/NCT05911711
NCT05911711
Recruiting
Not Applicable

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

Kangdong Sacred Heart Hospital1 site in 1 country120 target enrollmentJuly 7, 2023
ConditionsSepsis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
Kangdong Sacred Heart Hospital
Enrollment
120
Locations
1
Primary Endpoint
up to 1 day ICU mortality"
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Sepsis, a severe response to bacterial infection, lacks understanding of immunometabolic features that can identify high-risk patients. This study aimed to discover immune, biological, and metabolic biomarkers in sepsis patients with poor prognosis and understand the underlying mechanisms of host immune responses.

Detailed Description

Sepsis is a life-threatening condition resulting from a dysregulated host response to infection and remains a significant global health crisis. Accurately identifying high-risk patients and understanding the underlying mechanisms of distinct host responses are crucial. Dysregulation of immune and biological responses, along with metabolic remodeling, has emerged as a prevalent characteristic in sepsis patients. However, there is still a need for a comprehensive understanding of specific markers related to immunometabolism and the underlying mechanisms contributing to the disturbance in sepsis pathogenesis. This study aims to investigate the immune, biological, and metabolic profiles of sepsis patients, focusing on the alteration of metabolism in sepsis patients with poor outcomes. The findings of this study will provide valuable insights into dysregulated immunometabolism, shedding light on its contribution to the potentiation of immunopathogenesis in sepsis. Eligibility Criteria adults over the age of 19 a sepsis patient in ICU Patients are excluded from the study If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a Do not resuscitation(DNR) patient a patient under the age of 18 Outcome Measure ICU mortality, 28 days mortality Use of inotropics, vasopressors CRRT(continuous renal replacement therapy), ECMO (Extracorporeal membrane oxygenation), Interventional lung assist, polymyxin

Registry
clinicaltrials.gov
Start Date
July 7, 2023
End Date
June 7, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

So Young Park

associate professor

Kangdong Sacred Heart Hospital

Eligibility Criteria

Inclusion Criteria

  • adults over the age of 19 a sepsis patient in ICU

Exclusion Criteria

  • If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a DNR patient a patient under the age of 18

Outcomes

Primary Outcomes

up to 1 day ICU mortality"

Time Frame: up to 1 day ICU mortality"

up to 1 day ICU mortality"

Secondary Outcomes

  • 28 days mortality(28 days mortality)

Study Sites (1)

Loading locations...

Similar Trials